Prevalence of Autism Spectrum Conditions in Mainland China
NCT ID: NCT02065193
Last Updated: 2014-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
280000 participants
OBSERVATIONAL
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Large population-based screening This study will be conducted in urban areas but not rural areas across mainland China. One city of each region will participate, and in total there will be 14 cities for screening. Within each city, a number of 40 to 60 ordinary primary schools will be randomly selected from the defined region. All the students who are in 1st to 4th grade will asked to participate in order to form a sample of approximately 20,000 students.
Screening questionnaires The screening pack includes the Chinese CAST, the AQ-Child, the AQ-Adult short version (10 items), and risk factors questionnaire. An information sheet and consent form will be included in the pack as well.
2. Further assessments We expect approximately 5% on the CAST will score positive in ordinary school population. Thus, for a 20,000 sample, we would expect 900 positives (90% response rate). All the screen-positives and a random selected 5% from borderline group will be invited for clinical assessment. The diagnosis of clinical assessment will be divided into three categories: definite ASC, suspected ASC, and non-ASC. Then all the children with clinical assessment results as definite ASC and suspected ASC and a randomly selected 10-20 non-ASC will be invited for research diagnostic assessment using the ADOS and ADI-R, as well as RPM as IQ test. After that, the consensus diagnosis between ADOS/ADI-R assessment and the clinical diagnosis will be the final diagnosis.
3. Case identification in special schools All the children in special schools or training institutes in study region will be asked to fill in the screening pack. The children who do not attend any ordinary or special schools will be identified according to their residential ID in the studied regions. All screen-positives in special education will be assessed using the ADOS and ADI-R. Then those who met the criteria of ASC on ADOS or/and ADI-R will be assessed by psychiatrists and the clinical diagnosis will be the final diagnosis.
If we combine the prevalence of ordinary schools and special schools together, we will get an estimate of the prevalence of ASC in school-population in China. If we combine all the cases identified from schools and from residential records, we will generate an estimate of the prevalence of ASC in the general population in mainland China.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
National Study on Autism Spectrum Disorder in China
NCT02200679
Early Socioemotional Intervention for Children With Autism Spectrum Disorder in Hong Kong and Mainland China
NCT04658043
Psychometric Studies of the Chinese Versions of the SRS, CAST, and AQ
NCT01247662
The Real World Study of Autism Spectrum Disorder in China
NCT04358744
The Evaluation of Care Demand and Intervention Models for Individuals With ASD in Taiwan
NCT03676660
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Beijing group
ADOS/ADI-R/Clinical assessment
Guangdong group
ADOS/ADI-R/Clinical assessment
Shenzhen group
ADOS/ADI-R/Clinical assessment
Shanxi group
ADOS/ADI-R/Clinical assessment
Liaoning group
ADOS/ADI-R/Clinical assessment
Jilin group
ADOS/ADI-R/Clinical assessment
Heilongjiang group
ADOS/ADI-R/Clinical assessment
Jiangsu group
ADOS/ADI-R/Clinical assessment
Zhejiang group
ADOS/ADI-R/Clinical assessment
Fujian group
ADOS/ADI-R/Clinical assessment
Henan group
ADOS/ADI-R/Clinical assessment
Hubei group
ADOS/ADI-R/Clinical assessment
Hunan group
ADOS/ADI-R/Clinical assessment
'Shanxi group
ADOS/ADI-R/Clinical assessment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADOS/ADI-R/Clinical assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All children aged 6-11 years old.
Exclusion Criteria
* Children who are not found from ordinary schools, private training centres, public special schools and community household with the help of local residence records will not be included for this study.
6 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Disabled Persons Federation
OTHER_GOV
Chinese University of Hong Kong
OTHER
University of Cambridge
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sophia Xiang Sun
Cambridge-CUHK International Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carol Brayne, MD
Role: PRINCIPAL_INVESTIGATOR
University of Cambridge
Simon Baron-Cohen, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Cambridge
Carrie Allison, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Cambridge
Hong You, MD
Role: PRINCIPAL_INVESTIGATOR
China Disabled Persons Federation
Jibin Han, Master
Role: PRINCIPAL_INVESTIGATOR
China Disabled Persons Federation
Sian Griffiths, MD
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Huso Yi, PhD
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Xiang Sun, PhD
Role: PRINCIPAL_INVESTIGATOR
Cambridge/CUHK
Fiona E Matthews, PhD
Role: PRINCIPAL_INVESTIGATOR
MRC Biostatistics Unit
Bonnie Auyeung, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Cambridge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian CDPF
Fuzhou, Fujian, China
Shenzhen CDPF
Shenzhen, Guangdong, China
Heilongjiang CDPF
Jiamusi, Heilongjiang, China
Luoyang CDPF
Luoyang, Henan, China
Hengyang CDPF
Hengyang, Hunan, China
Jilin Mingzhi Centre
Jilin, Jilin, China
Liaoning CDPF
Benxi, Liaoning, China
Shanxi CDPF
Changzhi, Shanxi, China
Shanxi CDPF
Xian, Shanxi, China
Beijing CDPF
Beijing, , China
Guangdong CDPF
Guangzhou, , China
Zhejiang CDPF
Hangzhou, , China
Hubei CDPF
Wuhan, , China
Jiangsu CDPF
Yangzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Qiulan Wu
Role: primary
Zhenzhong Mao
Role: primary
Wei Peng
Role: primary
Zhanwei Chen
Role: primary
Zhengrong Dai
Role: primary
Donghong Su
Role: primary
Jiaqiu Li
Role: primary
Xiaofei Gao
Role: primary
Yong Li
Role: primary
Jianrong Liu
Role: primary
Yuwen Hua
Role: primary
Qin Li
Role: primary
Yue Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
China SCORE study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.